𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

✍ Scribed by Allan J. Wailoo; Nick Bansback; Alan Brennan; Kaleb Michaud; Richard M. Nixon; Fred Wolfe

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
96 KB
Volume
58
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A cost-effectiveness analysis of treatme
A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
✍ Hyon K. Choi; John D. Seeger; Karen M. Kuntz πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Objective: Recently, new treatment options for rheumatoid arthritis (ra) patients with an inadequate response to methotrexate (mtx) have become available. given the wide variability in efficacy and costs among these different treatment options, we sought to determine their cost-effectiveness (ce

Impact of the medicare modernization act
Impact of the medicare modernization act of 2003 on utilization and spending for medicare part B–covered biologics in rheumatoid arthritis
✍ Jalpa A. Doshi; Pengxiang Li; Andrea Puig πŸ“‚ Article πŸ“… 2010 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 111 KB πŸ‘ 2 views

## Abstract ## Objective To examine changes in utilization and expenditures for infliximab in rheumatoid arthritis (RA) patients associated with the 2 changes implemented by the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, specifically 1) reductions in physician reim